Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse

Overview of attention for article published in Frontiers in oncology, February 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 27 X posts from 21 X users, with an upper bound of 53,477 followers.

RT @Myeloma_Doc: #Myeloma Paper of the Day: Study assessing molecular residual disease by circulating tumor DNA (ctDNA) finds 14/15 post-AH…

RT @Abdallah81MD: My thoughts that ctDNA will be the future of how to change the treatment before relapsed MM and MRD testing in BMBx will…

RT @Myeloma_Doc: #Myeloma Paper of the Day: Study assessing molecular residual disease by circulating tumor DNA (ctDNA) finds 14/15 post-AH…

RT @Myeloma_Doc: #Myeloma Paper of the Day: Study assessing molecular residual disease by circulating tumor DNA (ctDNA) finds 14/15 post-AH…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 23 additional X posts.